XT
ADCT icon

XTX Topco’s ADC Therapeutics ADCT Stock Holding History

XTX Topco’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
140,341
+122,919
+706% +$359K ﹤0.01% 3380
2026
Q1 		$65.3K Sell
17,422
-65,449
-79% -$258K ﹤0.01% 3247
2025
Q4 		$293K Sell
82,871
-8,708
-10% -$35.3K 0.01% 2095
2025
Q3 		$366K Buy
+91,579
New +$289K 0.02% 1345
2024
Q4 		– Sell
-115,073
Closed -$362K – 2229
2024
Q3 		$362K Buy
115,073
+58,210
+102% +$184K 0.03% 1064
2024
Q2 		$180K Buy
56,863
+32,034
+129% +$127K 0.02% 1278
2024
Q1 		$111K Sell
24,829
-18,821
-43% -$69.4K 0.02% 1344
2023
Q4 		$72.5K Sell
43,650
-23,401
-35% -$21.6K 0.02% 1177
2023
Q3 		$60.1K Sell
67,051
-139,316
-68% -$185K 0.01% 1257
2023
Q2 		$444K Sell
206,367
-59,892
-22% -$135K 0.08% 442
2023
Q1 		$519K Buy
266,259
+68,624
+35% +$253K 0.11% 269
2022
Q4 		$759K Buy
197,635
+187,267
+1,806% +$749K 0.16% 146
2022
Q3 		$50K Buy
+10,368
New +$75.1K 0.01% 1024

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

XTX Topco's ADCT Position: Q2 2026 in Review

XTX Topco increased its ADC Therapeutics (ADCT) stake by 706% in Q2 2026, buying an estimated $359K and bringing the position to 140,341 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

XTX Topco first reported a position in ADCT in Q3 2022 and has held it in 13 quarters since. The position peaked at $759K in Q4 2022. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • XTX Topco held 140,341 shares of ADC Therapeutics worth $150K as of Q2 2026.
  • XTX Topco bought 122,919 ADC Therapeutics shares in Q2 2026, an estimated $359K.
  • ADC Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3380 holding.
  • XTX Topco first reported a position in ADC Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • XTX Topco's ADC Therapeutics position peaked at $759K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.